SMTI — Sanara Medtech Income Statement
0.000.00%
- $281.93m
- $296.25m
- $86.67m
- 55
- 28
- 71
- 51
Annual income statement for Sanara Medtech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | C2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 15.6 | 24.1 | 45.8 | 65 | 86.7 |
Cost of Revenue | |||||
Gross Profit | 14 | 21.8 | 39.5 | 57.1 | 78.5 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 20 | 31.5 | 58.4 | 69.2 | 93.4 |
Operating Profit | -4.45 | -7.38 | -12.5 | -4.22 | -6.72 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -4.45 | -7.99 | -13.9 | -4.44 | -9.91 |
Provision for Income Taxes | |||||
Net Income After Taxes | -4.45 | -7.99 | -8.09 | -4.44 | -9.91 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -4.36 | -7.92 | -7.94 | -4.3 | -9.66 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -4.36 | -7.92 | -7.94 | -4.3 | -9.66 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.862 | -1.08 | -1 | -0.52 | -0.807 |